Fulfillment of Postmarketing Requirements to the FDA for Therapies Granted Oncology Indications Between 2011 and 2016.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 29801111.
- Also identified by DOI 10.1001/jamaoncol.2018.0610 and PMC identifier 6145721.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
This data analysis examines the fulfillment of postmarketing requirements associated with drugs granted accelerated approval for oncology indications in the past 6 years.
Medical subject headings
- Medical Oncology
- Neoplasms